1. Adverse events.
Study | Events in EDTA arm | n in EDTA arm | Events in placebo arm | n in placebo arm |
Guldager 1992 Combined events |
111 | 80 | 74 | 79 |
Guldager 1992 Hypocalcaemic symptoms |
6 | 80 | 2 | 79 |
Guldager 1992 Fatigue |
12 | 80 | 11 | 79 |
Guldager 1992 Faintness |
11 | 80 | 1 | 79 |
Guldager 1992 Gastrointestinal symptoms |
11 | 80 | 7 | 79 |
Guldager 1992 Serum‐creatinine increase |
7 | 80 | 9 | 79 |
Guldager 1992 Proteinuria |
10 | 80 | 4 | 79 |
Guldager 1992 Phlebitis at infusion site |
35 | 80 | 28 | 79 |
Guldager 1992 Pain at infusion site |
9 | 80 | 5 | 79 |
Guldager 1992 Headache |
7 | 80 | 7 | 79 |
Guldager 1992 Raynaud's Phenomenon |
1 | 80 | 0 | 79 |
Guldager 1992 Metallic taste |
1 | 80 | 0 | 79 |
Guldager 1992 Dermatitis |
1 | 80 | 0 | 79 |
TACT 2013 Combined events |
100 | 839 | 127 | 869 |
EDTA: ethylene diamine tetra‐acetic acid